Clinical Outcomes of Drug-Coated Balloons in Coronary Artery Disease Unsuitable for Drug-Eluting Stent Implantation.
Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
Randomized comparative study of diamond-like carbon coated stainless steel stent versus uncoated stent implantation in patients with coronary artery disease.
Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial.
Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, Wiebe J, Joner M, Hochholzer W, Laugwitz KL, Schunkert H, Kastrati A, Kufner S.
Eur Heart J. 2023 Apr 17;44(15):1343-1357. doi: 10.1093/eurheartj/ehad026.
Drug-coated balloons for coronary artery disease: current concepts and controversies.
Buccheri D, Lombardo RM, Cortese B.
Future Cardiol. 2019 Nov;15(6):437-454. doi: 10.2217/fca-2019-0009. Epub 2019 Nov 5.
Sirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial.
Greco A, Sciahbasi A, Abizaid A, Mehran R, Rigattieri S, de la Torre Hernandez JM, Alfonso F, Cortese B.
Catheter Cardiovasc Interv. 2022 Oct;100(4):544-552. doi: 10.1002/ccd.30358. Epub 2022 Sep 2.
Clinical Outcomes of Drug-Coated Balloons in Coronary Artery Disease Unsuitable for Drug-Eluting Stent Implantation.
Iijima R, Kougame N, Hara H, Moroi M, Nakamura M.
Circ J. 2018 Jul 25;82(8):2025-2031. doi: 10.1253/circj.CJ-18-0121. Epub 2018 Jun 12.
Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial.
Scheller B, Ohlow MA, Ewen S, Kische S, Rudolph TK, Clever YP, Wagner A, Richter S, El-Garhy M, Böhm M, Degenhardt R, Mahfoud F, Lauer B.
EuroIntervention. 2020 Apr 17;15(17):1527-1533. doi: 10.4244/EIJ-D-19-00723.
Drug-Coated Balloons in the Management of Coronary Artery Disease.
Korjian S, McCarthy KJ, Larnard EA, Cutlip DE, McEntegart MB, Kirtane AJ, Yeh RW.
Circ Cardiovasc Interv. 2024 May;17(5):e013302. doi: 10.1161/CIRCINTERVENTIONS.123.013302. Epub 2024 May 21.
Vascular healing in high-bleeding-risk patients at 3-month after everolimus-eluting stent versus biolimus A9-coated stent implantation: insights from analysis of optical coherence tomography and coronary angioscopy.
Koiwaya H, Nishihira K, Kadooka K, Kuriyama N, Shibata Y.
Cardiovasc Interv Ther. 2023 Jan;38(1):64-74. doi: 10.1007/s12928-022-00877-9. Epub 2022 Aug 2.
Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
Tijssen RYG, Kraak RP, Lu H, Mifek JG, Carlyle WC, Donohoe DJ, De Winter RJ, Koch KT, Wykrzykowska JJ.
Expert Rev Med Devices. 2017 May;14(5):325-334. doi: 10.1080/17434440.2017.1318057. Epub 2017 Apr 24.
Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease: A PRISMA-compliant meta-analysis of randomized clinical trials.
Lu W, Zhu Y, Han Z, Wang X, Wang X, Qiu C.
Medicine (Baltimore). 2017 Mar;96(12):e6397. doi: 10.1097/MD.0000000000006397.
Coronary stent failure: role of a blended approach with drug-coated balloons for complex lesions.
Cortese B, Sanchez-Jimenez E, Lazar L.
Minerva Cardiol Angiol. 2024 Jun;72(3):266-280. doi: 10.23736/S2724-5683.22.06172-5. Epub 2023 Mar 20.
